ArticleMolecular metabolism2023
GIP receptor agonism blocks chemotherapy-induced nausea and vomiting.
Article in Molecular metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Central relaxin-3/RXFP3 signaling potently drives orexigenic behaviors and attenuates cisplatin-induced anorexia and body weight loss.iScience · 2026Article
- Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.Nature metabolism · 2026Article
- Clinical Potential of GIP in Type 2 Diabetes and Obesity.Diabetes care · 2026Review
- Functional segregation of body-brain signals in the area postrema.bioRxiv : the preprint server for biology · 2026Article
- GIPR signaling modulates PYY-induced hypophagia and malaise in rodents.Molecular metabolism · 2026Article
- GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.Cell reports · 2026Article
- Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.Frontiers in pharmacology · 2026Review
- Incretin hormones and obesity.The Journal of physiology · 2025Review
- Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism.Cell metabolism · 2025Article
- GIP receptor agonism suppresses inflammation-induced aversion and food intake via distinct circuits.bioRxiv : the preprint server for biology · 2025Article
- Characterizing Brainstem GLP-1 Control of Sensory-Specific Satiety in Male and Female Rats Across the Estrous Cycle.Biological psychiatry · 2025Article
- A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity.Diabetes · 2025Review
- Review
- Hindbrain octadecaneuropeptide gliotransmission as a therapeutic target for energy balance control without nausea or emesis.Science translational medicine · 2025Article
- Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.Science advances · 2025Article
- Molecular Design of Unimolecular Tetra-Receptor Agonists.Journal of the American Chemical Society · 2025Article
- Ventral hippocampus neurons encode meal-related memory.Nature communications · 2025Article
- Central mechanisms of emesis: A role for GDF15.Neurogastroenterology and motility · 2025Review
- Convergent state-control of endogenous opioid analgesia.bioRxiv : the preprint server for biology · 2025Article
- The role of GIPR in food intake control.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveNausea and vomiting remain life-threatening obstacles to successful treatment of chronic diseases, despite a cadre of available antiemetic medications. Our inability to effectively control chemotherapy-induced nausea and vomiting (CINV) highlights the need to anatomically, molecularly, and functionally characterize novel neural substrates that block CINV.
methodsBehavioral pharmacology assays of nausea and emesis in 3 different mammalian species were combined with histological and unbiased transcriptomic analyses to investigate the beneficial effects of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism on CINV.
resultsSingle-nuclei transcriptomics and histological approaches in rats revealed a topographical, molecularly distinct, GABA-ergic neuronal population in the dorsal vagal complex (DVC) that is modulated by chemotherapy but rescued by GIPR agonism. Activation of DVCGIPR neurons substantially decreased behaviors indicative of malaise in cisplatin-treated rats. Strikingly, GIPR agonism blocks cisplatin-induced emesis in both ferrets and shrews.
conclusionOur multispecies study defines a peptidergic system that represents a novel therapeutic target for the management of CINV, and potentially other drivers of nausea/emesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.